Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

MLA

Arndt Borkhardt, et al. “Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-Driven Medulloblastoma While Making Them Susceptible to Anti-CD47-Induced Macrophage Phagocytosis via NF-KB-TGM2 Driven Tumor Inflammation.” Journal for ImmunoTherapy of Cancer, vol. 11, no. 1, Jan. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2022-005871.

APA

Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, … Siddhartha Mitra. (2023). Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. Journal for ImmunoTherapy of Cancer, 11(1). https://doi.org/10.1136/jitc-2022-005871

Chicago

Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, et al. 2023. “Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-Driven Medulloblastoma While Making Them Susceptible to Anti-CD47-Induced Macrophage Phagocytosis via NF-KB-TGM2 Driven Tumor Inflammation.” Journal for ImmunoTherapy of Cancer 11 (1). doi:10.1136/jitc-2022-005871.